key: cord-0779440-vaohwbcz
authors: Castagna, Alberto; Ruotolo, Giovanni; Manzo, Ciro
title: Progress in the risk assessment of hydroxychloroquine in frail elderly people
date: 2020-12-25
journal: Aging Med (Milton)
DOI: 10.1002/agm2.12140
sha: 52b524c4bfa39ea2e17688ddfd7b9251d9ccf6ce
doc_id: 779440
cord_uid: vaohwbcz

Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti‐inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID‐19 pandemic. However, HCQ can cause QT interval prolongation. The current therapies used in COVID‐19 are changing as the pandemic develops. The aim of this article is to promote a validated risk score for QT prolongation in multidimensional assessment of COVID‐19 patients, especially in elderly and polypathological patients.

COVID-19 has been declared a global pandemic by the World Health Organization 1 . Currently, we are lacking therapeutic options. 2 Some observational studies have suggested the benefits of hydroxychloroquine (HCQ) for the treatment of COVID-19. 2 As a result, these treatments are increasingly used off-label for patients with COVID- 19 . Over the past few decades, HCQ has received wide attention as an antiviral drug. Wang et al 3 in 2014 revealed that HCQ activates the host antiviral innate immunity. This drug accumulates in the cellular organelles, creating an acidic environment and inhibiting the replication of different viruses by interfering with endosome/ lysosome trafficking or viral protein maturation. 4 Clinical trials have revealed that HCQ is able to act as a potential drug in fighting against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). [6] [7] HCQ is structurally and mechanistically similar to the class IA antiarrhythmic quinidine, which inhibits voltage-gated sodium and potassium channels, prolonging the QT interval and increasing the risk of torsades de pointes (TdP) and sudden cardiac death. 8 Chloroquine's reported risk of sudden cardiac death is limited to cases of hypotension due to vasodilation and negative inotropy resulting from rapid parenteral administration of the medication or situations of self-inflicted overdose. 9 The risk of QT prolongation and TdP with HCQ is limited to a series of case reports in patients with either chronic use or overdose. 10 In patients treated with HCQ and azithromycin, Chorin et al observed prolongation of the corrected QT interval (QTc) from a baseline average of 435 ± 24 ms (mean ± SD) to a maximal average value of 463 ± 32 ms (P < .001 [one-sample t-test]), which occurred on Day 3.6 ± 1.6 of therapy. 11 Mercuro et al observed that patients who received HCQ for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTc. 12 Large population data from the US National Health and Nutrition Examination Survey II and III studies reported that heart-rate-QTc variance on an electrocardiogram (ECG) increases with age, and specifically, prolonged QTc is more prevalent in older individuals. 13 In addition, prolonged QTc is associated with an increased risk of incident cardiovascular event or cardiovascular death. 14 The QT interval is an indirect measure of the duration of ventricular depolarization and repolarisation. 15 A prolongation of the QT interval and an increased QTc are associated with an increased rate of cardiovascular morbidity and mortality. This is related to electrical instability and the risk of ventricular arrhythmogenesis. 16, 17 QTc increases with age may be due to a combination of factors. Aging is associated with alterations in the amount of sympathetic and parasympathetic tone that can alter myocardial repolarization and the duration of the QTc. 18, 19 The relationship between advancing age and QT interval might be explained by the changes in heart and vasculature observed in elderly subjects. These include cardiac hypertrophy, increased vascular stiffness, and aortic impedance. The increase in vascular impedance, in conjunction with its effects leading to an increase in systolic arterial pressure, means that the pulsate component of external cardiac work must increase. 20 The stroke work, expressed as the product of stroke volume and systolic blood pressure, has been shown to increase with age in clinically normotensive subjects. This occurs even in elderly subjects in whom stroke volume at rest is decreased compared to younger subjects. 21 In addition, traditional cardiovascular disease risk markers gradually lose their predictive value with age. 22, 23 The main reason for this high prevalence is that Italy is the second oldest nation in the world. In fact, like other pathological conditions common in elderly patients, the mortality rate of COVID-19 is directly related to the patient's age, frailty, and comorbidities. 24 Finally, recent data suggest that frailty-related phenotypes are associated with QTc prolongation. Michishita et al reported that inactivity and light-intensity physical activity were associated with QTc in older adults. 25 The analysis of the data collected with the Comprehensive Geriatric Assessment is particularly useful and effective in the management of geriatric symptoms and syndromes, especially in situations of complexity/emergency, the recent COVID-19 pandemic among these. 26 Pre-existing cardiovascular diseases are widely represented in these patients and are associated with a poorer prognosis. 24 Beyond the acquired association between pre-existing cardiovascular diseases and the severity of respiratory infections with negative outcome for patients, attention should be focused on cardiovascular complications directly associated with COVID-19. Very often in COVID-19 patients, especially in severe forms evolving into acute respiratory distress syndrome, cardiac injury appears with increased troponin values, 27,28 which are not necessarily associated with an acute coronary syndrome, as they can also be related to non-ischemic forms, such as myocarditis. 29 The destabilization of a pre-existing coronary plaque, mediated by the systemic inflammatory process with consequent rupture of the fibrous cap, exposure of thrombogenic material, and thrombotic occlusion of the vessel, represents the most probable pathogenetic hypothesis. The inflammatory state contributes to this sequence of events through several determinants, such as the release of inflammatory cytokines, sympathetic hyperactivation, increased free radicals and wall stress, tachycardia, hypoxia, and finally a state of increased thrombophilia. 24 QT interval prolongation is recognized as an ECG sign that portends an increased risk for TdP. 36 This specific risk increases as the QTc increases. 37, 38 Further, the risk of TdP related to a drug may be greater in polytherapy patients. Indeed, polytherapy patients show other risk factors, such as heart disease, advanced age, electrolyte abnormalities, bradycardia, and kidney or liver disease. 35, 39, 40 A significant number of hospitalized patients with QTc prolongation receive QT-interval-prolonging drugs, which increase the risk of arrhythmia. 40 As a consequence, identifying patients with highest risk of drug-induced QTc prolongation could facilitate measures to modify the risk. The problem could be solved by giving discontinuously QT-interval prolonging drugs, when possible.

Tisdale et al found a valid method to quantify the risk of drug-induced QTc prolongation. 41 The QTc prolongation risk score could be incorporated into multidimensional assessment to alert clinicians if the patient reveals a risk of drug-induced QTc prolongation. The evaluation of QTc prolongation risk score includes the QTc-prolonging value because the drugs are considered as a risk factor. Among the drugs able to prolong the QT interval we can mention anesthetic, antiarrhythmic, antidepressant, anticancer, antiemetic, antifungal, antimalarial, antipsychotic, and antibiotic medications. 42 Their classifications are preferably based on the degree of QTc prolongation they induce: three points for taking one QTc-prolonging drug and three additional points for taking ≥2 QTc-prolonging drugs (for a total of six points). Later, the score could be classified as low risk (≤6 points), moderate risk (7-10 points), or high risk (≥11 points). Caution is advised when combining QT-prolonging medications or when using these medications in patients with electrolyte abnormalities. 43 In the elderly patient in polytherapy, use of HCQ must be considered in relation to other risk factors. For instance, we have to evaluate how drugs included in polytherapy interact with HCQ metabolism. Indeed, HCQ is substrate for cytochrome P450 (CYP) enzymes (enzymes responsible for the metabolism of many drugs) and HCQ can interfere with other drugs. 44 Finally, smoking has previously been suspected to interfere with the bioavailability of HCQ. 45 The findings from Mehra 46 and colleagues' study add to preliminary reports suggesting that regimens of chloroquine or HCQ , alone or with azithromycin, are not useful and could be harmful in hospitalized patients with COVID-19. 47 Boulware et al 48 reported the results of a randomized trial testing HCQ as post-exposure prophylaxis for COVID-19, but the results are more provocative than definitive, suggesting that the potential prevention benefits of HCQ remain to be determined. 49 This element could lead clinicians to select lower-risk drug therapy, apply more intense QTc monitoring in susceptible patients, or implement other interventions to mitigate the risk (such as closer monitoring of serum electrolyte concentrations). On ClinicalTrials.gov, a total of 2,935 studies related to COVID-19 were registered on August 7, 2020.

A minority of clinical trials related to COVID-19 registered on ClinicalTrials.gov planned to evaluate cardiovascular therapies and were estimated for completion after December 2020. Collectively, these findings underscore the need for a network of sites with a platform protocol for rapid evaluation of multiple therapies and generalizability to inform clinical care and health policy for COVID-19 moving forward. 50 The worldwide use of HCQ, beyond COVID-19, requires a careful analysis of the risk factors for QTc prolongation in order to reduce the resulting arrhythmic risk.

However, the simultaneous presence of several risk factors, very common in frail elderly patients with comorbidities, suggests the use of a multifactorial analysis model, in addition to the traditional comprehensive geriatric assessment. 51 

In our opinion, in clinical practice, the use of HCQ in the frail elderly must be used in a prudent way. ECG control is fundamental given the unpredictability, and it is prudent to correct electrolyte disorders and, where possible, avoid or minimize use of other drugs known to prolong the QT interval in relation to comorbidity and polypharmacotherapy. 52 The current therapies used in COVID-19 are changing according to the developing pandemic. Further study of the need for QT interval monitoring is needed before final recommendations can be made. Therefore, our article has been created to describe how multidimensional assessment, combined with a valuation of drug-interaction risk in polypathological patients, remains a priority in the therapeutic management of all patients, including those with COVID-19.

No funders had a role in writing the article or the decision to submit for publication.

Nothing to disclose.

Conceptualization: A.C., C.M., and G.R. Data curation: A.C. and G.R. 

COVID-19) events as they happen

Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review

Hydroxychloroquine-Inhibited Dengue Virus Is Associated with Host Defense Machinery

Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial

The cardiotoxicity of antimalarials: Malaria Policy Advisory Committee Meeting

Cardiotoxicity of antimalarial drugs

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin

Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)

The QT interval historically treated

Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice

The QT interval

QT dispersion: an indicator of arrhythmia risk in patients with long QT intervals

The prognostic value of the QT interval and QT dispersion in all-cause mortality and morbidity in a population of Danish citizens

Differential changes of autonomic nervous system function with age in man

Physiological mechanisms influencing cardiac repolarization and QT interval

An analysis of the time-relations of electrocardiograms

Similar myocardial effects of aging and hypertension

Prognostic value of cardiovascular disease status: the Leiden 85-plus study

Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study

Coronavirus disease 2019 (covid-19) and cardiovascular disease: a vicious circle

Association between the physical activity and heart rate corrected-QT interval in older adults

Comment on: coronavirus 2019 in geriatrics and long-term care: the ABCDs of COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV 2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Prevention of torsades de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation

Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes

Torsade de pointes due to quinidine: observations in 31 patients

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. www.medrxiv.org

Covid-19 and renal disease in elderly patients

Psychomotor agitation following treatment with hydroxychloroquine

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation

The long QT syndrome. Prospective longitudinal study of 328 families

Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group

Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs. A prospective, observational study in a large urban academic medical center in the US

Kidney function and cognitive decline in frail elderly: two faces of the same coin?

Kovacs development and validation of a risk score to predict QT interval prolongation in hospitalized patients

Drug-induced QT interval prolongation and torsades de pointes; Role of the pharmacist in risk assessment, prevention and management

QT Prolonging Drugs. StatPearls

Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article

Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? Lancet. The www.thelancet

A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19

Hydroxychloroquine for the prevention of Covid-19 searching for evidence

Characteristics of clinical trials evaluating cardiovascular therapies for coronavirus disease 2019 Registered on ClinicalTrials.gov. A cross sectional analysis

Ruotolo Hydroxychloroquine and QTc beylond COVID.19. Geriatric Care

The role of hydroxychloroquine sulfate in the geriatric patient with coronavirus disease 2019 (COVID-19)

Progress in the risk assessment of hydroxychloroquine (HCQ) in frail elderly people